KIF5B-RET融合基因存在于部分非小细胞肺癌(NSCLC)中,是除EGFR、k-ras、EML4-ALK驱动基因之外另一个重要的酪氨酸激酶抑制剂作用靶点。该融合基因在不吸烟或少量吸烟、腺癌、无EGFR及k-ras突变、无EML4-ALK融合基因的NSCLC患者中发生率较高,并且对RET抑制剂(如凡德他尼)有较好的治疗反应。全文就KIF5B-RET融合基因的基本结构、功能、检测及其在NSCLC中的研究进展进行综述。 KIF5B-RET fusion gene is present in some non-small cell lung cancer (NSCLC) and is another important tyrosine kinase inhibitor besides EGFR, k-ras and EML4-ALK driving genes. This fusion gene has a high prevalence in NSCLC patients without smoking or with small amounts of smoking, adenocarcinoma, mutations without EGFR and k-ras, and without the EML4-ALK fusion gene, and with RET inhibitors such as vandetanib Good treatment response. This review summarizes the basic structure, function and detection of KIF5B-RET fusion gene and its research progress in NSCLC.